Selective modulation of activated protein C activities by a nonactive site-targeting nanobody library.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
11 Jul 2023
Historique:
accepted: 24 01 2023
received: 10 08 2022
medline: 3 7 2023
pubmed: 4 2 2023
entrez: 3 2 2023
Statut: ppublish

Résumé

Activated protein C (APC) is a pleiotropic coagulation protease with anticoagulant, anti-inflammatory, and cytoprotective activities. Selective modulation of these APC activities contributes to our understanding of the regulation of these physiological mechanisms and permits the development of therapeutics for the pathologies associated with these pathways. An antibody library targeting the nonactive site of APC was generated using llama antibodies (nanobodies). Twenty-one nanobodies were identified that selectively recognize APC compared with the protein C zymogen. Overall, 3 clusters of nanobodies were identified based on the competition for APC in biolayer interferometry studies. APC functional assays for anticoagulant activity, histone H3 cleavage, and protease-activated receptor 1 (PAR1) cleavage were used to understand their diversity. These functional assays revealed 13 novel nanobody-induced APC activity profiles via the selective modulation of APC pleiotropic activities, with the potential to regulate specific mechanisms for therapeutic purposes. Within these, 3 nanobodies (LP2, LP8, and LP17) inhibited all 3 APC functions. Four nanobodies (LP1, LP5, LP16, and LP20) inhibited only 2 of the 3 functions. Monofunction inhibition specific to APC anticoagulation activity was observed only by 2 nanobodies (LP9 and LP11). LP11 was also found to shift the ratio of APC cleavage of PAR1 at R46 relative to R41, which results in APC-mediated biased PAR1 signaling and APC cytoprotective effects. Thus, LP11 has an activity profile that could potentially promote hemostasis and cytoprotection in bleedings associated with hemophilia or coagulopathy by selectively modulating APC anticoagulation and PAR1 cleavage profile.

Identifiants

pubmed: 36735416
pii: 494329
doi: 10.1182/bloodadvances.2022008740
pmc: PMC10331410
doi:

Substances chimiques

Protein C 0
Receptor, PAR-1 0
Single-Domain Antibodies 0
Anticoagulants 0
Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3036-3048

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL104165
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142975
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL148096
Pays : United States

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

J Thromb Haemost. 2007 Jul;5 Suppl 1:81-94
pubmed: 17635714
N Engl J Med. 2001 Mar 8;344(10):699-709
pubmed: 11236773
Blood. 2000 Jul 15;96(2):585-93
pubmed: 10887122
World J Biol Chem. 2014 May 26;5(2):169-79
pubmed: 24921007
J Biol Chem. 2007 Nov 9;282(45):33022-33
pubmed: 17872949
Biomolecules. 2021 Jul 31;11(8):
pubmed: 34439797
Nat Commun. 2020 Jun 12;11(1):2992
pubmed: 32532974
Nat Med. 2009 Nov;15(11):1318-21
pubmed: 19855397
J Neurosci. 2008 Nov 26;28(48):12788-97
pubmed: 19036971
J Cell Mol Med. 2018 Oct;22(10):4617-4629
pubmed: 30085397
Curr Pharm Des. 2013;19(42):7479-85
pubmed: 24372304
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4586-91
pubmed: 16537393
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Blood. 2012 Dec 20;120(26):5237-46
pubmed: 23149848
Blood. 2018 Jul 12;132(2):159-169
pubmed: 29866816
Thromb Haemost. 2005 Jul;94(1):60-8
pubmed: 16113785
Front Cell Neurosci. 2014 Oct 21;8:344
pubmed: 25374510
Thromb Haemost. 2001 Feb;85(2):218-20
pubmed: 11246535
Nucleic Acid Ther. 2020 Oct;30(5):276-288
pubmed: 32486960
Haemophilia. 2001 Sep;7(5):511-4
pubmed: 11554942
Blood Adv. 2022 Feb 8;6(3):959-969
pubmed: 34861695
Chem Biol. 2009 Apr 24;16(4):442-51
pubmed: 19389630
Ann Neurol. 2019 Jan;85(1):125-136
pubmed: 30450637
Thromb Haemost. 1999 Sep;82(3):1078-87
pubmed: 10494767
Blood. 2015 May 7;125(19):2898-907
pubmed: 25824691
Br J Haematol. 2011 Jun;153(5):644-54
pubmed: 21457218
Semin Immunopathol. 2012 Jan;34(1):127-32
pubmed: 21822632
Blood. 2014 Nov 27;124(23):3480-9
pubmed: 25320242
J Biol Chem. 2020 Nov 6;295(45):15236-15244
pubmed: 32855236
Res Pract Thromb Haemost. 2020 Sep 09;4(7):1087-1110
pubmed: 33134775
N Engl J Med. 2012 May 31;366(22):2055-64
pubmed: 22616830
Blood. 2004 Sep 15;104(6):1740-4
pubmed: 15178575
Blood. 2017 Jan 5;129(1):105-113
pubmed: 27789479
Nat Struct Biol. 1996 Sep;3(9):803-11
pubmed: 8784355
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
Blood. 2018 Mar 15;131(11):1163-1171
pubmed: 29343482
EMBO J. 1998 Jul 1;17(13):3512-20
pubmed: 9649422
Eur J Biochem. 1998 Mar 15;252(3):553-62
pubmed: 9546673
Blood. 1996 Aug 15;88(4):1183-7
pubmed: 8695835
Blood Adv. 2022 Jun 14;6(11):3304-3314
pubmed: 35390147
Nucleic Acid Ther. 2016 Dec;26(6):355-362
pubmed: 27736370
Blood. 2013 Aug 1;122(5):807-16
pubmed: 23788139
Shock. 2009 Dec;32(6):659-65
pubmed: 19333141
J Thromb Haemost. 2009 May;7(5):851-6
pubmed: 19320827
J Neurosci. 2013 Apr 3;33(14):6181-90
pubmed: 23554499
Blood. 2022 May 5;139(18):2830-2841
pubmed: 35143636

Auteurs

Derek S Sim (DS)

Coagulant Therapeutics Corporation, Berkeley, CA.

Meenal Shukla (M)

Department of Molecular Medicine, Scripps Research, La Jolla, CA.

Cornell R Mallari (CR)

Coagulant Therapeutics Corporation, Berkeley, CA.

José A Fernández (JA)

Department of Molecular Medicine, Scripps Research, La Jolla, CA.

Xiao Xu (X)

Department of Molecular Medicine, Scripps Research, La Jolla, CA.

Doug Schneider (D)

Consultants for Coagulant Therapeutics, Berkeley, CA.

Maxine Bauzon (M)

Consultants for Coagulant Therapeutics, Berkeley, CA.

Terry W Hermiston (TW)

Coagulant Therapeutics Corporation, Berkeley, CA.

Laurent O Mosnier (LO)

Department of Molecular Medicine, Scripps Research, La Jolla, CA.

Articles similaires

UK Foot and Ankle Thromboembolism (UK-FATE).

Jitendra Mangwani, Linzy Houchen-Wolloff, Karan Malhotra et al.
1.00
Humans Venous Thromboembolism Male Female United Kingdom
Exosomes Humans Endothelial Cells Animals Epithelial-Mesenchymal Transition
Blood-Brain Barrier Claudin-5 Cadherins Glial Cell Line-Derived Neurotrophic Factor Animals

Antibodies get under the skin.

Chiara Levra Levron, Gabriele Piacenti, Giacomo Donati
1.00
Humans Skin Antibodies Sebaceous Glands Animals

Classifications MeSH